Mirikizumab 100mg/1ml solution for injection pre-filled disposable devices and Mirikizumab 200mg/2ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Mirikizumab
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Mirikizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mirikizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Mirikizumab on the MHRA register
Omvoh 100mg/1ml solution for injection pre-filled pens and Omvoh 200mg/2ml solution for injection pre-filled pens
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(4)
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Ulcerative colitis: management (NG130)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 20 · Randomised trials: 22 · 2019–2026
Showing the 50 most relevant studies, sorted by most relevant.
Taimoor Ashraf, A. K. Malani, Dileep Kumar, et al.
Frontiers in Medicine, 2025
Geert D’Haens, Marla Dubinsky, Taku Kobayashi, et al.
New England Journal of Medicine, 2023
Maryam Falah, Leen Alhamd, Fatma Bayoumi, et al.
The Egyptian Journal of Internal Medicine, 2026
Shrouk F. Mohamed, M. R. Abdelraouf, Mohamed Wagdy, et al.
Naunyn-Schmiedeberg's Archives of Pharmacology, 2025
Joel Gabin Konlack Mekontso, Joseph Yvan Bena Nnang, Samuel G. J. Fodop, et al.
American Journal of Gastroenterology, 2025
Mohamed Karam Allah Elkholy
OSF Registries, 2024
Mohamed A. Abu Elainein, Sama S. ElSherefy, Norhan M. Yousef, et al.
BMC Gastroenterology, 2025
Xuan Wang, Lytske Bakker, Navneet Upadhyay, et al.
Inflammatory Bowel Diseases, 2024
Ankit Gulati, Neha Mittal, Sunanda Kane, et al.
Journal of Medical Economics, 2025
Xuemei Chen, Guifei Si, Yuquan Li, et al.
Medicine, 2025
Background: This meta-analysis explores the efficacy and safety of mirikizumab in treating IBD. Methods: A comprehensive search was conducted encompassing randomized controlled trials examining the efficacy of mirikizumab in treating IBD across PubMed, Embase, Cochrane Library, and Web of Science, with a search deadline of November 1, 2023. Quality assessment leaned on the Cochrane manual risk-of-bias evaluation, while Stata 15 undertook the data analysis. Results: Three randomized controlled studies involving 1602 individuals were finally included. Our meta-analysis suggested that mirikizumab can improve clinical remission (RR = 2.11, 95% CI [1.74, 2.55]), clinical response (RR = 1.68, 95% CI [1.50, 1.89]), endoscopic remission (RR = 1.95, 95% CI [1.65, 2.31]), histologic–endoscopic mucosal improvement (RR = 1.92, 95% CI [1.60, 2.32]) in inflammatory bowel disease (IBD). Conclusion: According to our meta-analysis, mirikizumab is a promising drug in the treatment of IBD.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
9.3 days
Mechanism
Mirikizumab is a monoclonal antibody directed against the p19 subunit of human interleukin-23 (IL-23).
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
44%
[L48646]
…
Half-life
9.3 days
[L48646]
Volume of distribution
4.83 L
[L48646]
Metabolism
[L48646]
Clearance
0.0229 L/h
[L48646]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.[L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with moderate-to-severely active ulcerative colitis.
[L48646][L48656][L48661]
It is also indicated for the treatment of adult patients with moderately to severely active Crohn’s disease in adults.
[L52360]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 359 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L48646]
The site of subcutaneous injection did not significantly influence mirikizumab bioavailability. The estimated steady-state Cmax, AUCtau, and Ctrough of mirikizumab following subcutaneous administration in patients with ulcerative colitis were 10.1 μg/mL, 160 μg*day/mL, and 1.70 μg/mL, respectively.
[L48646]
The estimated steady-state Cmax, AUCtau, and Ctrough of mirikizumab following intravenous infusion in patients with ulcerative colitis were 99.7 μg/mL, 538 μg*day/mL, and 2.75 μg/mL, respectively.
[L48646]
[L48646]
[L48646]
[L48646]
[L48646]
Proteins and enzymes this drug interacts with in the body
PMID:11114383
Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 .
PMID:29287995 PMID:32474165 PMID:33606986
This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A .
PMID:12023369
In turn, participates in the early and effective intracellular bacterial clearance .
PMID:32474165
Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells PMID:17676044
PMID:8605935 PMID:8943050
IL-12 is primarily produced by professional antigen-presenting cells (APCs) such as B-cells and dendritic cells (DCs) as well as macrophages and granulocytes and regulates T-cell and natural killer-cell responses, induces the production of interferon-gamma (IFN-gamma), favors the differentiation of T-helper 1 (Th1) cells and is an important link between innate resistance and adaptive immunity .
PMID:1673147 PMID:1674604 PMID:8605935
Mechanistically, exerts its biological effects through a receptor composed of IL12R1 and IL12R2 subunits .
PMID:8943050
Binding to the receptor results in the rapid tyrosine phosphorylation of a number of cellular substrates including the JAK family kinases TYK2 and JAK2 .
PMID:7528775
In turn, recruited STAT4 gets phosphorylated and translocates to the nucleus where it regulates cytokine/growth factor responsive genes .
PMID:7638186
As part of IL-35, plays essential roles in maintaining the immune homeostasis of the liver microenvironment and also functions as an immune-suppressive cytokine (By similarity). Mediates biological events through unconventional receptors composed of IL12RB2 and gp130/IL6ST heterodimers or homodimers .
PMID:22306691
Signaling requires the transcription factors STAT1 and STAT4, which form a unique heterodimer that binds to distinct DNA sites PMID:22306691
ATC L04AC24
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mirikizumab
Additional database identifiers
Drugs Product Database (DPD)
23863
HUGO Gene Nomenclature Committee (HGNC)
HGNC:15488
GenAtlas
IL23A
GeneCards
IL23A
GenBank Gene Database
AF301620
UniProt Accession
IL23A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5969
GeneCards
IL12A
UniProt Accession
IL12A_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72